antibodi
develop
date
use
therapeut
target
cellular
mediat
overexpress
diseas
cytokin
rheumatoid
arthriti
cellsurfac
marker
oncolog
antitumor
necrosi
factor
antitnf
antibodi
use
rheumatoid
arthriti
although
initi
load
dose
reduc
exist
inflammatori
signal
longterm
use
provid
prophylaxi
relaps
first
candid
approv
infliximab
initi
approv
intraven
use
dose
mgkg
recent
antibodi
develop
subcutan
inject
adalimumab
taken
market
leader
inject
everi
week
clearli
complianc
link
rel
eas
deliveri
subcutan
approach
reason
dose
infecti
diseas
biggest
success
stori
use
antibodi
provid
prophylaxi
infect
respiratori
syncyti
viru
rsv
rsv
respons
million
episod
new
lower
respiratori
tract
infect
particularli
target
children
year
younger
result
estim
death
global
estim
palivizumab
dose
mgkg
given
monthli
intramuscular
inject
throughout
rsv
season
suitabl
small
babi
would
appeal
adult
followon
phase
ii
clinic
studi
time
potent
palivizumab
vitro
develop
singl
mg
inject
cover
typic
season
taken
togeth
case
illustr
initi
proof
concept
possibl
find
secondgener
antibodi
simpl
rout
deliveri
suffici
potenc
support
rel
infrequ
dose
field
major
object
use
mab
infecti
diseas
therapeut
class
high
price
presum
consequ
high
cost
good
manufactur
cost
particularli
import
attribut
medic
develop
diseas
poverti
low
middleincom
countri
lmic
howev
product
effici
mab
increas
dramat
recent
decad
cellcultur
express
level
around
gl
even
higher
common
publish
analysi
decad
ago
alreadi
note
cost
mab
product
drop
us
us
produc
scale
potenti
use
larg
l
reactor
recent
analysi
similar
estim
process
us
us
public
health
applic
infecti
diseas
lmic
intramuscular
subcutan
deliveri
would
prefer
rather
intraven
rout
intramuscular
rout
effect
limit
dose
inject
volum
ml
probabl
close
maximum
accept
small
children
antibodi
typic
solubl
around
mgml
give
limit
total
dose
around
mg
correspond
rang
mgkg
taken
togeth
cost
good
inject
base
current
number
would
rang
us
us
benchmark
cost
difficult
comparison
recent
launch
malaria
vaccin
provid
less
protect
inject
around
us
programmat
cost
protect
child
malaria
year
sahel
use
exist
lowcost
oral
medicin
estim
us
unitaid
inject
therapeut
could
protect
child
season
price
provid
costeffect
option
import
factor
manag
reduct
frequenc
administr
make
prophylaxi
use
resourcepoor
set
mab
use
therapi
gener
igg
immunoglobulin
gs
plasma
halfliv
day
human
antibodi
use
provid
sever
month
protect
case
onceperseason
antirsv
antibodi
nirsevimab
discuss
earlier
generel
peptid
anticgrp
fremanezumab
recent
approv
prevent
migrain
dose
mg
everi
month
altern
simpli
increas
dose
would
increas
halflif
circul
mab
sever
strategi
propos
mutat
made
igg
fc
fragment
crystalliz
region
interact
receptor
respons
uptak
antibodi
mutat
significantli
extend
mab
plasma
halflif
mutat
deriv
neonat
fc
receptor
fcrn
increas
strength
interact
fc
region
fc
receptor
acid
ph
condit
lysosom
result
complex
recycl
back
cell
surfac
escap
degrad
approach
follow
bevacizumab
cetuximab
mutat
leu
ser
discuss
even
longer
period
protect
stimul
recent
result
viral
mediat
express
antibodi
target
hiv
technolog
hold
promis
sustain
serum
titer
antibodi
year
singl
inject
although
technolog
develop
complic
direct
inject
antibodi
one
final
object
goal
administ
monoclon
vaccin
would
instead
provid
lifelong
coverag
howev
diseas
develop
longlast
potent
vaccin
still
remain
elus
mani
pathogen
rais
adequ
immun
respons
due
immunosuppress
final
antibodi
give
immedi
protect
import
rapidli
evolv
epidem
pandem
individu
deploy
zone
high
transmiss
antibodi
would
thu
form
part
overal
armamentarium
along
drug
bed
net
insecticid
vaccin
first
foremost
develop
mab
question
suitabl
antigen
target
virus
simplest
pathogen
genom
allow
limit
mean
evad
host
immun
therefor
passiv
activ
vaccin
success
area
therapeut
antibodi
develop
market
respiratori
syncyti
varicella
zoster
vaccinia
hepat
b
virus
hbv
histor
immun
respons
virus
consid
pure
cellular
type
pathogen
mostli
humor
antibodi
base
less
effect
howev
nowaday
interplay
system
better
understood
instanc
therapeut
opportun
virus
rabi
reli
passiv
immun
mab
target
initi
stage
infect
may
provid
prophylaxi
repertoir
potenti
antigen
approach
greatli
help
increas
avail
genom
transcript
inform
passiv
immun
especi
effect
infect
rabi
viru
avoid
apoptosi
infect
neuron
kill
protect
cell
carrier
mount
immun
respons
recent
review
list
mab
nanobodi
singlechain
type
antibodi
produc
camelid
current
clinic
trial
unit
state
addit
polyclon
antibodi
approv
european
union
us
cytomegaloviru
hepat
virus
c
postexposur
prophylaxi
measl
rabi
rubella
tetanu
approach
appear
suitabl
viru
infect
protect
consequ
snake
venom
might
also
appli
type
diseas
fewer
market
antibodi
target
bacteria
target
toxin
name
anthrax
clostridium
cytotoxin
pauciti
may
due
lack
discoveri
effort
consequ
histor
avail
cheap
effect
antibiot
howev
worri
rise
antibiot
resist
tide
turn
immun
protist
parasit
fungi
gener
ineffect
one
problem
organ
trypanosoma
brucei
caus
sleep
sick
plasmodium
malari
parasit
encod
dozen
even
hundr
differ
surfac
antigen
sequenti
expos
abund
stage
outpac
host
immun
system
pathogen
clinic
trial
infect
patient
possibl
desir
case
inhal
anthrax
raxibacumab
approv
use
fda
anim
rule
provid
rout
forward
diseas
area
trial
infect
human
patient
possibl
ethic
recent
case
discov
mab
neglect
tropic
infecti
diseas
review
work
took
broad
categorywid
approach
virus
bacteria
parasit
also
includ
venom
snake
bite
challeng
envenom
repres
seriou
health
problem
result
death
yearli
recent
includ
world
health
organ
list
neglect
tropic
diseas
discoveri
mab
area
logic
follow
longstand
therapeut
success
passiv
immun
cost
feasibl
develop
mab
recent
review
includ
specif
clinic
develop
regulatori
challeng
review
select
diseas
priorit
global
health
innov
technolog
ghit
fund
intern
collabor
public
privat
sector
support
collabor
japanes
nonjapanes
entiti
advanc
global
health
research
develop
present
vaccin
discoveri
status
diseas
list
tabl
human
schistosomiasi
caus
infect
mainli
one
speci
blood
fluke
belong
schistosomatoidea
estim
million
case
annual
africa
twothird
schistosoma
haematobium
remaind
mansoni
southeast
asia
speci
japonicum
mekongi
caus
smaller
number
infect
mortal
associ
schistosom
infect
difficult
calcul
comorbid
link
anemia
common
infect
haematobium
lead
femal
genit
schistosomiasi
result
increas
suscept
hiv
infect
life
cycl
parasit
complex
involv
snail
human
host
infect
stage
cercaria
migrat
penetr
human
host
skin
becom
schistosomula
move
venou
circul
initi
lung
matur
parasit
migrat
via
heart
portal
circul
intestin
egg
excret
fece
pass
bladder
wall
urin
prophylaxi
could
therefor
either
prevent
entri
surviv
suppress
kill
juvenil
adult
worm
clearli
malari
parasit
stage
parasit
life
cycl
inhibit
effect
protect
molecular
target
best
address
antibodi
still
clear
life
cycl
differ
character
schistosomula
recov
lung
elong
resist
antibodydepend
cellmedi
cytotox
newli
transform
schistosomula
praziquantel
standard
treatment
schistosomiasi
act
adult
worm
effect
juvenil
thu
repeat
treatment
requir
elimin
worm
patient
ideal
treatment
would
therefor
kill
adult
juvenil
worm
submicromolar
concentr
effect
target
candid
profil
small
molecul
inhibitor
targetproduct
profil
tpp
prophylaxi
schistosomiasi
publish
possibl
start
build
one
recent
character
praziquantel
use
murin
model
pediatr
clinic
treatment
reduc
infect
use
dose
mgkg
murin
model
infect
mansoni
cercaria
maximum
dose
mgkg
kill
adult
worm
howev
murin
dose
produc
peak
exposur
ngml
higher
exposur
observ
children
recommend
regimen
mgkg
seem
pragmat
project
antibodi
reduc
worm
burden
mous
model
dose
clinic
achiev
human
could
accept
maxim
practic
inject
antibodi
children
mgkg
given
rel
consist
allometri
human
mice
mab
correspond
dose
mice
target
identif
schistosomiasi
straightforward
unlik
malaria
vaccin
field
offer
clue
use
antibodi
target
two
vaccin
candid
current
test
human
first
base
fatti
acidbind
protein
fabp
schistosoma
test
small
openlabel
pilot
studi
seneg
larger
trial
uganda
plan
vaccin
base
schistosoma
expect
report
clue
possibl
way
forward
term
antigen
select
come
varieti
areasfirst
schistosoma
helminth
flatworm
initi
immun
respons
characterist
strong
helper
cytokin
reaction
seen
viral
bacteri
infect
less
pronounc
protozoan
infect
cytokin
releas
includ
interleukin
il
drive
product
eosinophil
attack
parasit
drive
product
immunoglobulin
e
ige
epidemiolog
studi
endem
area
suggest
agedepend
immun
may
develop
infect
reinfect
treatment
good
correl
protect
develop
ige
antibodi
result
respons
hybridoma
produc
monoclon
ige
antibodi
japonicum
identifi
mab
protect
vitro
antigendepend
cellular
cytotox
assay
rat
macrophag
eosinophil
also
vivo
earli
phase
infect
recogn
kda
antigen
schistosoma
identifi
paramyosin
muscl
protein
uniqu
invertebr
epitop
paramyosin
recogn
determin
sequenc
inject
mice
paramyosin
provid
protect
mansoni
infect
japonicum
equival
protein
also
propos
vaccin
target
although
develop
report
taken
togeth
suggest
altern
approach
gener
therapeut
mab
would
produc
igg
mab
target
paramyosin
potenti
solubl
nonsurfac
antigen
second
beyond
cellsurfac
protein
schistosom
also
express
larg
number
glycan
part
glycoprotein
glycolipid
repertoir
antibodi
respons
glycan
mount
infect
host
case
specif
antibodi
produc
could
identifi
use
b
cell
clone
infect
mice
genet
modifi
express
human
antibodi
repertoir
interestingli
systemat
analysi
antibodi
produc
target
variou
stage
parasit
life
cycl
although
earli
work
mekongi
suggest
schistosomula
adult
worm
extract
would
induc
better
respons
addit
stimul
respons
schistosom
infect
suppress
tcell
activ
mansoni
use
distinct
mechan
suppress
tcell
activ
result
select
upregul
surfac
splenic
macrophag
presenc
fatigu
anerg
cell
open
possibl
cotherapi
low
dose
mab
program
cell
death
antibodi
revers
anergi
treatment
invas
fungal
infect
ifi
remain
major
challeng
worldwid
broadspectrum
antifung
drug
effect
substanti
toxic
concern
welltoler
drug
use
prophylact
frequent
induc
resist
even
best
current
treatment
risk
mortal
due
ifi
higher
lowincom
countri
figur
substanti
wors
mani
invas
infect
uniformli
fatal
without
treatment
estim
global
mortal
involv
fungal
infect
high
million
annual
addit
fungal
infect
caus
signific
comorbid
mortal
hiv
patient
model
studi
suggest
optim
therapi
could
save
live
million
hiv
patient
period
discuss
focu
mab
develop
follow
signific
fungal
pathogen
cryptococcu
pneumocysti
paracoccidioid
candida
addit
antibodi
directli
target
inhibit
fungal
pathogen
mab
direct
checkpoint
control
host
immun
respons
approach
may
particularli
use
fungal
pathogen
sustain
infect
character
shift
protect
respons
noninflammatori
respons
clinic
use
rheumatoid
arthriti
clearli
exacerb
fungal
infect
although
remain
seen
whether
clinic
use
effect
cryptococcu
neoforman
predominantli
caus
opportunist
infect
patient
hivaid
respons
larg
burden
aidsrel
diseas
death
subsaharan
africa
although
rate
infect
decreas
recent
year
greatli
improv
access
antiretrovir
therapi
art
mortal
infect
patient
declin
demonstr
failur
antifung
develop
keep
pace
improv
antivir
treatment
cryptococcosi
first
manifest
pulmonari
diseas
spread
hematogen
cerebrospin
fluid
brain
caus
mening
meningoenceph
ad
complex
cross
barrier
drug
develop
abil
mab
protect
lethal
cryptococc
infect
mice
first
demonstr
three
decad
ago
subsequ
work
demonstr
efficaci
variou
mab
target
polysaccharid
capsul
essenti
virul
factor
primari
interfac
cryptococcu
infect
among
mab
evalu
phase
clinic
trial
found
produc
modest
reduct
circul
cryptococc
antigen
develop
hamper
howev
difficulti
secur
fund
diseas
financi
return
like
common
problem
neglect
infecti
diseas
subsequ
studi
examin
mab
target
cryptococc
melanin
glucosylceramid
see
addit
vivo
vitro
exampl
host
also
target
stimul
immun
respons
addit
highlight
potenti
mab
therapeut
studi
demonstr
divers
inhibitori
action
mab
perform
cryptococc
cell
includ
opson
increas
phagocytosi
inhibit
fungal
growth
capsular
polysaccharid
releas
biofilm
format
antibodymedi
target
cleavag
augment
host
respons
pneumocysti
like
cryptococcu
import
opportunist
pathogen
hivaid
immunosuppress
patient
popul
estim
case
per
year
howev
unlik
cryptococcu
acquir
environ
pneumocysti
spp
commens
differ
speci
occur
lung
mani
mammal
capac
endogen
infect
acquisit
asymptomat
carrier
make
pneumocysti
attract
target
immunoprophylaxi
end
varieti
program
aim
develop
pneumocysti
vaccin
passiv
immun
studi
initi
use
mab
rais
pneumocysti
epitop
intranas
administr
mab
recogn
pneumocysti
kexinlik
protein
abl
prevent
transmiss
pneumocysti
pneumonia
infect
suscept
cohous
mice
demonstr
feasibl
approach
emerg
evid
import
b
immun
pneumocysti
infect
strongli
support
research
area
paracoccidioid
brasiliensi
less
global
preval
cryptococcu
pneumocysti
import
caus
ifi
latin
america
mab
rais
major
p
brasiliensi
antigen
glycoprotein
infect
mous
model
activ
mediat
mab
phagocytosi
p
brasiliensi
cell
increas
product
led
reduct
fungal
burden
mab
significantli
reduc
fungal
colonyform
unit
almost
complet
abolish
granuloma
format
lung
antibodi
rais
mous
regulatori
treg
cell
control
immun
excess
inflamm
deplet
cell
result
less
sever
tissu
inflamm
reduc
mortal
suscept
mice
demonstr
potenti
mab
exert
control
fungal
infect
either
directli
incapacit
fungal
cell
indirectli
via
modul
host
respons
candida
albican
commonli
isol
fungal
pathogen
global
associ
signific
morbid
mortal
particularli
patient
hiv
tuberculosi
tb
infect
recent
paper
demonstr
clone
antibodi
gene
b
cell
cultur
deriv
patient
infect
c
albican
antibodi
capabl
stimul
opsonophagocyt
macrophag
activ
provid
protect
murin
model
dissemin
candidiasi
summari
mab
offer
tremend
potenti
augment
antifung
arsen
anim
model
provid
promis
result
wide
rang
potenti
target
capac
inhibit
pathogen
augment
host
respons
may
possibl
target
divers
fungal
pathogen
appropri
mab
cocktail
target
panfung
antigen
use
mab
adjuv
exist
antifung
drug
also
show
promis
howev
note
mab
inhibitori
inde
may
worsen
infect
speci
strain
specif
issu
mechanist
basi
inhibit
differ
mab
vari
dramat
date
mab
treatment
advanc
clinic
trial
previous
mention
cryptococcu
mycograb
heat
shock
protein
specif
antibodi
fragment
show
promis
treat
candida
infect
fail
make
market
due
product
difficulti
unresolv
safeti
issu
antifung
immunomodul
complex
area
field
still
emerg
preliminari
studi
highlight
potenti
excit
new
advanc
mab
research
applic
understand
fungal
immun
manipul
tackl
lifethreaten
fungal
infect
dengu
fever
mosquitoborn
viral
infect
found
tropic
subtrop
region
around
world
dengu
viru
denv
transmit
femal
mosquito
mainli
speci
aed
aegypti
lesser
extent
albopictu
distinct
viru
serotyp
present
circul
endem
area
denv
infect
cell
human
immun
system
cell
type
lead
symptom
includ
high
fever
sever
headach
sever
pain
behind
eye
joint
pain
muscl
bone
pain
rash
mild
bleed
sever
case
plasma
leak
circulatori
system
fatal
global
incid
dengu
grown
dramat
recent
decad
one
recent
studi
estim
approxim
million
peopl
infect
million
manifest
clinic
year
estim
global
peopl
sever
dengu
requir
hospit
year
infect
lethal
antibodydepend
enhanc
ade
problemat
dengu
infect
presenc
subneutr
level
flaviviru
crossreact
serum
antibodi
act
one
member
viru
famili
may
result
increas
infect
via
ade
anoth
viru
member
serotyp
observ
particularli
secondari
dengu
infect
despit
decad
effort
effect
treatment
dengu
current
dengvaxia
approv
fda
licens
dengu
vaccin
world
also
live
attenu
tetraval
dengu
vaccin
develop
sanofi
pasteur
approv
sever
countri
howev
interim
result
longterm
safeti
followup
studi
demonstr
increas
risk
hospit
vaccinesensit
individu
suggest
aderel
concern
relev
report
nonneutr
level
antidenv
antibodi
enhanc
viral
entri
host
cell
form
denvantibodi
complex
concern
incomplet
antibodi
denv
may
caus
ademedi
sever
dengu
diseas
henc
need
safe
highli
efficaci
dengu
therapi
vaccin
provid
immun
serotyp
simultan
mab
therapi
altern
vaccin
therapi
dengu
mani
mab
dengu
mice
human
character
use
mab
also
explor
therapeut
option
antibodi
identifi
singapor
immunolog
network
neutral
dengu
serotyp
decreas
viremia
serotyp
mice
given
day
infect
human
mab
visterra
panserotyp
antidenv
develop
visterra
bind
e
protein
domain
iii
ediii
neutral
serotyp
denv
also
show
use
antivir
util
mgkg
mgkg
administ
day
post
infect
nonhuman
primat
infecti
viru
could
detect
either
plaqu
assay
viru
isol
treatment
find
howev
mirror
revers
transcript
pcr
rtpcr
find
human
challeng
model
avail
clinic
research
dengu
model
efficaci
safeti
profil
therapeut
antibodi
evalu
rapidli
smallscal
clinic
set
prior
tradit
largescal
field
studi
natur
infect
patient
develop
mab
dengu
therapi
import
consid
approach
prevent
reduc
ade
sever
studi
address
link
undertaken
neutral
human
mab
target
fusion
loop
domain
ii
show
strong
neutral
activ
denv
serotyp
howev
subneutr
concentr
also
elicit
ade
activ
vitro
reduc
ade
injampa
cowork
modifi
antibodi
fc
domain
posit
modifi
antibodi
kept
crossneutr
activ
serotyp
wildtyp
antibodi
lack
ade
activ
serotyp
subneutr
concentr
anoth
neutral
mab
leucin
alanin
mutat
engin
fc
part
abrog
bind
fc
gamma
receptor
mutant
fc
version
protect
mice
ade
complet
abrog
similarli
fragment
crystalliz
region
mutfc
mab
unabl
bind
cell
receptor
potenti
ade
use
prophylact
therapi
passiv
immun
mab
mgkg
reduc
viral
load
diseas
progress
nonhuman
primat
therapeut
antibodi
also
use
prophylaxi
afford
immedi
reliabl
protect
tb
good
exampl
gap
pathogen
preval
burden
mycobacterium
tuberculosi
spread
easili
among
human
popul
present
onethird
human
infect
new
infect
occur
popul
year
among
billion
carrier
howev
million
activ
tb
infect
million
death
thu
vast
major
carrier
keep
pathogen
check
tb
exert
level
immun
evas
one
maintain
latent
state
one
break
free
caus
activ
diseas
sever
studi
test
antibodi
therapi
tb
vari
success
review
even
mab
treatment
would
cur
shorten
standard
treatment
patient
infect
multidrugresist
mdr
extens
drugresist
xdr
strain
would
repres
major
advanc
addit
checkpoint
blockad
chronic
tb
infect
requir
consider
role
protect
antibodi
malaria
demonstr
year
ago
find
passiv
transfer
sera
mice
radiationattenu
sporozoit
delay
develop
infect
mice
tpp
malaria
well
describ
includ
profil
season
malaria
chemoprevent
treatment
success
launch
subsaharan
africa
last
year
consist
full
treatment
cours
day
amodiaquin
dose
sulfadoxinepyrimethamin
given
monthli
children
raini
season
antibodi
therapeut
malaria
could
prevent
entri
initi
infect
parasit
block
entri
sporozoit
liver
cell
block
entri
merozoit
erythrocyt
block
uptak
gametocyt
mosquito
break
transmiss
cycl
one
difficulti
target
merozoit
symptomat
malaria
extracellular
phase
pathogen
rel
shortliv
small
part
life
cycl
addit
number
merozoit
invad
erythrocyt
larg
compar
number
sporozoit
invad
liver
stage
dozen
interest
place
interven
mab
initi
infect
liver
current
mab
publish
potent
activ
circumsporozoit
protein
csp
reduc
parasitaemia
sporozoiteinfect
frg
tripl
mutant
mice
carri
human
liver
implant
mab
includ
clone
b
cell
obtain
patient
recent
rt
vaccin
trial
circumsporozoit
protein
set
includ
clone
patient
vaccin
irradi
sporozoit
antibodi
block
invas
process
red
blood
cell
merozoit
repres
anoth
possibl
approach
studi
merozoit
protein
reticulocytebind
protein
homologu
potenti
vaccin
antibodi
describ
could
block
cycl
erythrocyt
infect
specif
merozoit
epitop
character
could
form
basi
secondgener
antibodi
gener
observ
plasmodium
infect
human
host
unabl
mount
steril
immun
respons
one
theori
parasit
control
tcell
respons
induc
state
fatigu
anergi
similar
seen
tumorinvad
lymphocyt
immunooncolog
sever
studi
mice
demonstr
block
cytotox
tlymphocyteassoci
protein
improv
clearanc
mice
infect
plasmodium
bergheii
similar
experi
strong
argument
made
revers
fatigu
mild
checkpoint
inhibitor
blockad
may
way
facilit
host
respons
mab
therapi
also
propos
hiv
case
hiv
recent
review
two
mab
phase
iii
trial
pro
cenicriviroc
pro
target
cysteinecystein
chemokin
receptor
type
recent
enter
phase
iibiii
trial
weekli
subcutan
dose
monotherapi
mainten
cenicriviroc
dual
antagonist
investig
number
indic
includ
hiv
infect
note
earlier
ibalizumab
recent
approv
secondlin
treatment
hiv
treatment
hbv
infect
hypothesi
high
circul
hbsag
level
prevent
proper
immun
respons
novel
mab
evalu
reduc
hbsag
level
patient
addit
hbv
protein
target
discoveri
therapeut
mab
case
viscer
leishmaniasi
vl
glucocorticoidinduc
protein
consid
mab
target
systemat
analysi
antigen
report
clone
b
cell
infect
patient
although
mab
made
massiv
impact
control
autoimmun
diseas
inflamm
cancer
rel
impact
world
infecti
diseas
larg
confin
viral
diseas
use
mab
protect
rsv
infect
profil
secondgener
antibodi
show
possibl
obtain
mab
suffici
potent
provid
longterm
protect
singl
intramuscular
subcutan
inject
develop
new
technolog
clone
antibodi
b
cell
plasma
cell
taken
patient
infect
bacteria
virus
fungi
even
protozo
pathogen
possibl
quickli
obtain
fulli
human
antibodi
collect
potenti
activ
pathogen
vitro
vivo
technolog
express
antibodi
stage
uncommon
see
extrem
high
level
express
cell
cultur
taken
togeth
progress
reduc
cost
product
cost
good
antibodi
inject
start
enter
rang
us
us
reach
edg
afford
infecti
diseas
neglect
popul
studi
mutat
fc
region
confirm
mab
halfliv
extend
goal
singl
inject
cover
entir
season
infect
season
possibl
new
technolog
viral
deliveri
offer
promis
singl
inject
could
give
protect
even
longer
period
mani
infecti
diseas
see
buildup
portfolio
potenti
antibodi
case
littl
progress
made
systemat
attempt
need
identifi
antibodi
result
success
control
infect
patient
beyond
basic
antibodi
avail
new
monoclon
antiinfect
activ
vivo
would
open
door
even
creativ
option
bispecif
antibodi
could
use
key
immun
cell
could
effect
support
natur
respons
infect
studi
anim
model
chronic
malaria
infect
led
observ
result
reduct
impact
cytotox
cell
modul
treg
capac
lead
exhaust
ineffect
tcell
respons
clinic
trial
alreadi
underway
use
immun
checkpoint
blocker
chronic
hiv
hbv
infect
import
implic
infecti
diseas
singl
infect
drive
steril
immun
respons
diseas
includ
malaria
one
question
longer
term
whether
immun
checkpoint
inhibit
interf
signal
could
use
two
decad
ago
one
biggest
challeng
work
antiinfect
drug
discoveri
need
new
medicin
activ
widest
rang
pathogen
recent
time
tide
chang
clinic
diagnosi
medicin
high
degre
select
specif
often
long
show
good
clinic
activ
shift
highli
specif
medicin
favor
use
mab
given
overal
rise
interest
new
treatment
infecti
diseas
caus
concern
antimicrobi
resist
real
opportun
progress
newli
emerg
famili
mab
target
infecti
diseas
neglect
popul
outdat
preconcept
class
therapeut
research
fund
alloc
discoveri
result
eggandchicken
problem
absenc
conspicu
success
drive
addit
effort
one
goal
analysi
present
promot
make
addit
fund
avail
pursu
initi
discoveri
mab
neglect
diseas
